照常行事无法提供我们所需的新冠疫苗。
Business-as-Usual will not Deliver the COVID-19 Vaccines We Need.
作者信息
Torreele Els
机构信息
Institute for Innovation and Public Purpose (IIPP), University College London, London, UK.
出版信息
Development (Rome). 2020;63(2-4):191-199. doi: 10.1057/s41301-020-00261-1. Epub 2020 Nov 9.
Abstract
Governments must become active shapers of medical innovation and drive the development of critical health technologies as global health commons. The 'race' for COVID-19 vaccines is exposing the deficiencies of a business-as-usual medical innovation ecosystem driven by corporate interests, not health outcomes. Instead of bolstering collective intelligence, it relies on competition between proprietary vaccines and allows the bar on safety and efficacy to be lowered, risking people's health and undermining their trust.
摘要
政府必须积极塑造医学创新，并推动关键健康技术作为全球公共卫生资源的发展。新冠疫苗的“竞赛”正暴露了一个由企业利益而非健康结果驱动的常规医学创新生态系统的缺陷。它没有增强集体智慧，而是依赖于专利疫苗之间的竞争，还降低了对安全性和有效性的标准，危及人们的健康并损害他们的信任。
相似文献
1
Business-as-Usual will not Deliver the COVID-19 Vaccines We Need.照常行事无法提供我们所需的新冠疫苗。
Development (Rome). 2020;63(2-4):191-199. doi: 10.1057/s41301-020-00261-1. Epub 2020 Nov 9.
2
Strategies to Address COVID-19 Vaccine Hesitancy and Mitigate Health Disparities in Minority Populations.应对 COVID-19 疫苗犹豫和减轻少数族裔健康不平等的策略。
Front Public Health. 2021 Apr 23;9:645268. doi: 10.3389/fpubh.2021.645268. eCollection 2021.
3
The science commons in health research: structure, function, and value.健康研究中的科学共同体：结构、功能与价值。
J Technol Transf. 2007;32(3):133-156. doi: 10.1007/s10961-006-9016-9. Epub 2006 Dec 7.
4
A Commons for a Supply Chain in the Post-COVID-19 Era: The Case for a Reformed Strategic National Stockpile.后 COVID-19 时代供应链的 Commons：改革战略国家储备的案例。
Milbank Q. 2020 Dec;98(4):1058-1090. doi: 10.1111/1468-0009.12485. Epub 2020 Nov 2.
5
The COVID Pandemic and Surgical Innovation in the United States.新冠疫情与美国的外科创新。
Surg Innov. 2021 Apr;28(2):198-201. doi: 10.1177/15533506211005364. Epub 2021 Mar 27.
6
Vaccine Confidence and Hesitancy at the Start of COVID-19 Vaccine Deployment in the UK: An Embedded Mixed-Methods Study.新冠疫苗部署初期英国民众对疫苗的信心和犹豫：一项嵌入式混合方法研究。
Front Public Health. 2021 Nov 11;9:745630. doi: 10.3389/fpubh.2021.745630. eCollection 2021.
7
The role of good governance in the race for global vaccination during the COVID-19 pandemic.良好治理在 COVID-19 大流行期间全球疫苗接种竞赛中的作用。
Sci Rep. 2021 Nov 17;11(1):22440. doi: 10.1038/s41598-021-01831-0.
8
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.新冠疫苗的快速研发和早期成功为加速癌症治疗机制带来了希望。
Arch Razi Inst. 2021 Mar;76(1):1-6. doi: 10.22092/ari.2021.353761.1612. Epub 2021 Mar 1.
9
Vaccine safety in the next decade: why we need new modes of trust building.未来十年的疫苗安全：为何我们需要建立信任的新模式。
BMJ Glob Health. 2021 May;6(Suppl 2). doi: 10.1136/bmjgh-2020-003908.
10
Vaccines and Public Trust: Containing COVID-19 in Cuba.疫苗与公众信任：古巴控制新冠疫情
MEDICC Rev. 2022 Jan 31;24(1):9-13. doi: 10.37757/MR2022.V24.N1.11.
引用本文的文献
1
Which roads lead to access? A global landscape of six COVID-19 vaccine innovation models.哪些途径通向可及性？六种新冠疫苗创新模式的全球格局。
Global Health. 2024 Mar 26;20(1):25. doi: 10.1186/s12992-024-01017-z.
2
How to ensure a needs-driven and community-centred vaccination strategy for COVID-19 in Africa.如何在非洲确保一项以需求为导向、以社区为中心的新冠肺炎疫苗接种策略。
BMJ Glob Health. 2021 Feb;6(2). doi: 10.1136/bmjgh-2021-005306.
本文引用的文献
1
No-Fault Compensation for Vaccine Injury - The Other Side of Equitable Access to Covid-19 Vaccines.疫苗伤害的无过错补偿——公平获取新冠疫苗的另一面
N Engl J Med. 2020 Dec 3;383(23):e125. doi: 10.1056/NEJMp2030600. Epub 2020 Oct 28.
2
Regulatory Decision-making on COVID-19 Vaccines During a Public Health Emergency.公共卫生紧急状态下新冠疫苗的监管决策
JAMA. 2020 Oct 6;324(13):1284-1285. doi: 10.1001/jama.2020.17101.
3
COVID-19 vaccine trials should seek worthwhile efficacy.新冠病毒疫苗试验应追求有价值的疗效。
Lancet. 2020 Sep 12;396(10253):741-743. doi: 10.1016/S0140-6736(20)31821-3. Epub 2020 Aug 27.
4
The unequal scramble for coronavirus vaccines - by the numbers.新冠疫苗的不平等争夺——数据说明一切。
Nature. 2020 Aug;584(7822):506-507. doi: 10.1038/d41586-020-02450-x.
5
The rush to create a covid-19 vaccine may do more harm than good.急于研发新冠疫苗可能弊大于利。
BMJ. 2020 Aug 18;370:m3209. doi: 10.1136/bmj.m3209.
6
Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention.新冠病毒疫苗要成为预防或阻止疫情流行的唯一干预手段，必须有疫苗效力。
Am J Prev Med. 2020 Oct;59(4):493-503. doi: 10.1016/j.amepre.2020.06.011. Epub 2020 Jul 15.
7
Disease X: accelerating the development of medical countermeasures for the next pandemic.疾病 X：加速下一次大流行病医疗对策的研发。
Lancet Infect Dis. 2020 May;20(5):e108-e115. doi: 10.1016/S1473-3099(20)30123-7. Epub 2020 Mar 17.
8
[Science and technological innovation in health in Cuba: results in selected problemsCiência e inovação tecnológica em saúde em Cuba: resultados em problemas selecionados].[古巴卫生领域的科技创新：特定问题的成果 古巴卫生领域的科学与技术创新：选定问题的成果]
Rev Panam Salud Publica. 2018 Apr 24;42:e32. doi: 10.26633/RPSP.2018.32. eCollection 2018.
9
Bio-creep in non-inferiority clinical trials.非劣效临床试验中的生物渐进性。
Stat Med. 2010 Nov 30;29(27):2769-80. doi: 10.1002/sim.4053.
10
Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand.在欠发达世界维持抗逆转录病毒疗法的可及性：来自巴西和泰国的经验教训。
AIDS. 2007 Jul;21 Suppl 4:S21-9. doi: 10.1097/01.aids.0000279703.78685.a6.
Zotero 插件